logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
A

Andrew Blauvelt

university of maryland school of medicine

92H指数
807论文数
3.7W被引数
收录论文 314
发表时间
logo
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials德库拉伐替尼在日本中重度斑块状银屑病患者中的安全性和有效性：III期POETYK PSO-1、PSO-4试验及长期扩展试验的5年分析
errJOURNAL OF DERMATOLOGY
IF2.7
err2026-09-21
err0
errOAAI
errYukari Okubo; Akimichi Morita; Yayoi Tada; Shinichi Imafuku; April W. Armstrong; Andrew Blauvelt; John Vaile; Zoran Popmihajlov; Janice Li; Rajesh Sawant; Katsuyoshi Habiro; Katsuki Tsuritani; Mamitaro Ohtsuki
err分享
err收藏
Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial白癜风患者II期波伏西替尼试验中VASI结局的后续亚组分析和身体区域分析
errAdvances in Therapy
IF4
err2026-07-13
err0
errOAAI
errThierry Passeron; Amit G. Pandya; Khaled Ezzedine; Nanja van Geel; Lois Erskine; Leandro L. Santos; Zhenyi Xue; Andrew Blauvelt
err分享
err收藏
Benefit–risk profile comparison between dupilumab and upadacitinib: a structured benefit–risk assessment of the Heads Up trial度普利尤单抗与乌帕替尼的获益-风险特征比较：Heads Up试验的结构化获益-风险评估
errJournal of Dermatological Treatment
IF3.9
err2026-06-01
err0
errOAAI
errAndrew Blauvelt; Eric L. Simpson; Kilian Eyerich; Marjolein de Bruin-Weller; Sebastien Barbarot; Peter A. Lio; William Hurst; Stephanie Tcherny-Lessenot; Stephane Levy; Mike Bastian
err分享
err收藏
Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time真实世界证据表明，在银屑病患者中按需使用Bimekizumab剂量在一段时间内是安全有效的
errJournal of Personalized Medicine
IF3
err2026-04-28
err0
errOAAI
errCarlota Abbad-Jaime De Aragón; María Davo-Mogica; Pablo de la Cruz-Anaya; Emilio Berna-Rico; Inés Díaz-Ruiz; Inés Perales-Sánchez; Nicholas D. Brownstone; Pedro Jaén; Lluis Puig; Andrew Blauvelt; Alvaro González-Cantero
err分享
err收藏
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND特应性皮炎中度至重度患者接受特立珠单抗治疗长达6年的长期安全性与有效性：开放标签扩展试验ECZTEND的最终结果
errDermatology and Therapy
IF4.2
err2026-02-05
err0
errOAAI
errAndrew Blauvelt; H. Chih-Ho Hong; Norito Katoh; Richard G. Langley; Vivian Laquer; Aleksandra Lesiak; Ketty Peris; Julien Seneschal; Juan-Francisco Silvestre; Richard B. Warren; Andreas Wollenberg; Matthew Zirwas; Niels Højsager Bennike; Farzaneh Safavimanesh; Ann-Marie Tindberg; Kristian Reich
err分享
err收藏
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab一项随机第2期临床试验，旨在使用高诱导剂量risankizumab治疗中重度斑块状银屑病患者
errNature Communications
IF15.7
err2025-12-11
err0
errOAAI
errAndrew Blauvelt; Rundong Jiang; Linyu Shi; Lam C. Tsoi; Rachael Bogle; Jennifer Fox; Mehrnaz Gharaee-Kermani; Allison C. Billi; Robert T. Matheson; Huzefa Photowala; Johann E. Gudjonsson; Benjamin D. Ehst
err分享
err收藏
A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b StudyAmlitelimab STREAM-AD 二期研究的头颈部特应性皮炎与其他身体部位特应性皮炎的事后分析
errDermatology and Therapy
IF4.2
err2025-12-08
err0
errOAAI
errAdam Reich; Andrew Blauvelt; Stephan Weidinger; Vivian Y. Shi; Norito Katoh; Charles Lynde; Xinghua Gao; Nicole M. Armstrong; Charlotte Bernigaud; Kassim Rahawi
err分享
err收藏
361 Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis361 勒布rikizumab 每8周作为维持剂量使用可为中重度特应性皮炎患者提供长效应答
errJournal of Investigative Dermatology
IF5.7
err2025-11-10
err0
PREAI
errJonathan Silverberg; Vivian Laquer; Peter Lio; Kim Papp; Alan Irvine; Andrew Blauvelt; Hany Elmaraghy; Louise DeLuca-Carter; Heidi Crane; Gaia Gallo; Evangeline Pierce; Yuxin Ding; Amy Paller; Lucia Vidal
err分享
err收藏
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials特应性皮炎中度至重度成人患者中曲洛利单抗在不同种族亚组中的疗效与安全性：III期试验的事后分析
errAmerican Journal of Clinical Dermatology
IF8.8
err2025-10-21
err0
errOAAI
errTiffany Mayo; Jonathan I. Silverberg; April Armstrong; Emma Guttman-Yassky; Andrew Blauvelt; Ben Esdaile; Kenji Kabashima; Melinda Gooderham; Leon Kircik; Shannon Schneider; Niels Bennike; Rie von Eyben; Britta C. Martel; Mads A. Røpke; Norito Katoh; Andrew F. Alexis
err分享
err收藏
Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis: Recommendations from the International Psoriasis Council建立银屑病外用治疗效果不佳的定义共识：国际银屑病委员会的建议
errJournal of the American Academy of Dermatology
IF11.8
err2025-09-11
err0
PREAI
errBruce E. Strober; Andrew Blauvelt; Peter C.M.van de Kerkhof; Pravit Asawanonda; Rudi Chandra; Alvaro Gonzalez-Cantero; Cesar Gonzalez; Benjamin Hidalgo Matlock; Julia-Tatjana Maul; Filip Rob; Tiago Torres; Lone Skov
err分享
err收藏
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study阿利替利单抗（Amlitelimab），一种抗OX40配体抗体，用于治疗特应性皮炎：STREAM-AD临床研究的简明语言摘要
errImmunotherapy
IF2.9
err2025-09-01
err0
errOAAI
errStephan Weidinger; Andrew Blauvelt; Kim A. Papp; Adam Reich; Chih-Hung Lee; Margitta Worm; Charles Lynde; Yoko Kataoka; Peter Foley; Xiaodan Wei; Wanling Wong; Anne-Catherine Solente; Christine Weber; Samuel Adelman; Sonya Davey; Fabrice Hurbin; Natalie Rynkiewicz; Karl Yen; John T. O’Malley; Charlotte Bernigaud
err分享
err收藏
Comparative molecular analysis of IL-17A and IL-23 pathway inhibition in moderate-to-severe psoriasis: 4-week results from IXORA-R中重度银屑病中IL-17A与IL-23通路抑制的分子比较分析：IXORA-R研究4周结果
errJournal of Investigative Dermatology
IF5.7
err2025-08-15
err0
PREAI
errSandra Garcet; Lam C. Tsoi; Hong Hur; Andrew Blauvelt; Kim A. Papp; Bruce Konicek; Zhe Sun; Richard E. Higgs; Ernst R. Dow; David C. Gemperline; Gaia Gallo; Hany Elmaraghy; Brian J. Nickoloff; Venkatesh Krishnan; James G. Krueger; Johann E. Gudjonsson
err分享
err收藏
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results鲁索利昔单抗治疗中重度斑块状银屑病的长期安全性与有效性：最终LIMMitless III期开放标签扩展试验结果
errAmerican Journal of Clinical Dermatology
IF8.8
err2025-07-29
err0
errOAAI
errKim A. Papp; Mark G. Lebwohl; Lluís Puig; Mamitaro Ohtsuki; Stefan Beissert; Melinda Gooderham; Ahmad Z. Amin; Tianshuang Wu; Simone Rubant; Brenton Bialik; Doug Ashley; Ahmed M. Soliman; Michael M. Chen; Andrew Blauvelt
err分享
err收藏
Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16临床上有意义的改善：在未于第16周达到皮肤清除或近乎清除的中度至重度特应性皮炎青少年患者中使用Tralokinumab治疗的情况
errDermatology and Therapy
IF4.2
err2025-07-28
err0
errOAAI
errAmy S. Paller; Andrew Blauvelt; Weily Soong; H. Chih-ho Hong; Marie L. A. Schuttelaar; Shannon K. R. Schneider; Eric L. Simpson
err分享
err收藏
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab阿利替利单抗在特应性皮炎中临床结局评估的改进与维护
errJournal of the European Academy of Dermatology and Venereology
IF8
err2025-07-24
err0
errOAAI
errAndrew Blauvelt; Raj Chovatiya; Joseph F. Merola; Stephan Weidinger; Ken Igawa; Ella Brookes; Christine Weber; Jennifer Wang; Cori Gray
err分享
err收藏
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial德卡伐 Qinib（Deucravacitinib），一种口服、选择性、非竞争性酪氨酸激酶2抑制剂，在亚洲中重度银屑病患者中的研究：一项随机试验中患者报告结局的改善。
errdermatology
IF0
err2025-07-17
err0
errOAAI
errJianzhong Zhang; Yangfeng Ding; Ping Wang; Linfeng Li; Weili Pan; Yan Lu; Hao Cheng; Xian Jiang; Ji-Chen Ho; Shuping Guo; Seong Jun Seo; Linda Stein Gold; Andrew Blauvelt; Joe Zhuo; Yichen Zhong; Brandon Becker; Leona Liu; Subhashis Banerjee; Diamant Thaçi
err分享
err收藏
Psoriasis银屑病
errNature Reviews Disease Primers
IF60.6
err2025-06-26
err0
PREAI
errApril W. Armstrong; Andrew Blauvelt; Kristina Callis Duffin; Yu-Huei Huang; Laura J. Savage; Lily Guo; Joseph F. Merola
err分享
err收藏
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study口服Janus kinase 1抑制剂povorcitinib在广泛性白癜风患者中的疗效与安全性：一项2期、随机、双盲、剂量范围探索、安慰剂对照研究
errJournal of the American Academy of Dermatology
IF11.8
err2025-06-13
err0
errOAAI
errAmit G. Pandya; Khaled Ezzedine; Thierry Passeron; Nanja van Geel; Kurt Brown; Leandro L. Santos; Lois Erskine; Kofi Wagya; Andrew Blauvelt
err分享
err收藏
International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation国际银屑病协会银屑病疾病严重程度重新分类：有效性、接受度和实施情况的更新
errJournal of the American Academy of Dermatology
IF11.8
err2025-06-06
err0
errOAAI
errBruce E. Strober; Andrew Blauvelt; Peter CM. van de Kerkhof; Álvaro González-Cantero; Mona El-Kalioby; Cesar Gonzalez; Benjamin Hidalgo Matlock; Filip Rob; Pravit Asawanonda; Rudi Chandra; Julia-Tatjana Maul; Tiago Torres; Lone Skov
err分享
err收藏
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review (vol 42, pg 1360, 2025)SDZ-ADL（一种阿达木单抗生物类似药）在生物制剂初治和转换治疗的患者中治疗免疫介导性炎症性疾病的疗效、安全性和免疫原性：文献综述（卷42，页1360，2025）
errADVANCES IN THERAPY
IF4
err2025-04-28
err0
errOAAI
errWiland, P; Both, C; Gaylis, NB; Cohen, RD; Halfvarson, J; Lemke, L; von Richter, O; Blauvelt, A
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
D
Dafna D. Gladman
H 指数: 143 · 论文数: 1.6K
J
James G. Krueger
H 指数: 143 · 论文数: 746
S
Silvio Danese
H 指数: 139 · 论文数: 2.3K
C
C.E.M. Griffiths
H 指数: 131 · 论文数: 1.3K
R
Robert L. Modlin
H 指数: 127 · 论文数: 511
查看更多